Platzbecker, Uwe http://orcid.org/0000-0003-1863-3239
Santini, Valeria http://orcid.org/0000-0002-5439-2172
Komrokji, Rami S. http://orcid.org/0000-0002-1876-5269
Zeidan, Amer M.
Garcia-Manero, Guillermo http://orcid.org/0000-0002-3631-2482
Buckstein, Rena
Miteva, Dimana
Keeperman, Karen
Holot, Natalia
Nadal, Jose Alberto
Lai, Yinzhi
Vodala, Sadanand
Rosettani, Barbara
Giuseppi, Ana Carolina
Yucel, Aylin
Fenaux, Pierre
Article History
Received: 7 April 2023
Revised: 1 September 2023
Accepted: 7 September 2023
First Online: 26 September 2023
Competing interests
: UP has received grant support from Amgen, Janssen, Merck, and Novartis; grant and travel support, and lecture, steering committee, and consulting fees, and travel support from Celgene/BMS; and lecture fees from Novartis. VS has received honoraria and advisory board fees from BMS, travel support from Janssen, and advisory board fees from AbbVie, Geron, Gilead, Menarini, Novartis, Servier Pharmaceuticals, and Syros. RSK has received consulting and advisory board fees from Geron; speaker and advisory board fees from AbbVie, CTI BioPharma, Jazz Pharmaceuticals, PharmaEssentia, and Servier Pharmaceuticals; advisory board fees from Novartis, Rigel Pharmaceuticals, and Taiho Pharma; and funding and advisory board fees from BMS. AMZ has received consulting fees, research funding, honoraria, and travel support from Cardiff Oncology, Novartis, and Pfizer; consulting fees, research funding, and honoraria from AbbVie, Amgen, Aprea, Boehringer-Ingelheim, Celgene/BMS, Incyte, Otsuka, Takeda, and Trovagene; consulting fees, and honoraria from Acceleron Pharma, Agios, Astellas, BeyondSpring, Cardinal Health, Daiichi Sankyo, Epizyme, Geron, Gilead, Ionis Pharmaceuticals, Janssen, Jazz Pharmaceuticals, Kura Oncology, Seattle Genetics, Syndax, Taiho Pharma, Tyme; research funding from ADC Therapeutics, Astex Pharmaceuticals, AstraZeneca, and Medimmune. GG-M has received research funding from BMS. RB has received research funding and honoraria from BMS, and Taiho Pharma, and honoraria from AbbVie. DM, NH, BR, and AY are currently employed by BMS. JAN is currently employed by BMS, is a current holder of individual stocks in a privately held company, and a current holder of BMS stock options. KK is currently employed by, is a current holder of BMS stock options, and is a current holder of Pfizer stock options. YL, ACG, and SV are currently employed by, and current holders of BMS stock options. PF has received consulting fees, research funding, and honoraria from BMS.